Literature DB >> 18176115

Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel.

Walter J McConathy1, Maya P Nair, Sulabha Paranjape, Linda Mooberry, Andras G Lacko.   

Abstract

Reconstituted (synthetic) high-density lipoprotein particles carrying paclitaxel (rHDL/PTX) were prepared with substantially higher PTX content than reported earlier. The rHDL/PTX complexes seemed to be primarily spherical nanoparticles when examined via electron microscopy, with a constant composition, molecular weight and exceptional stability even after ultracentrifugation and storage for up to 6 months. The rHDL/PTX nanoparticles had superior cytotoxicity against several cancer cell lines (MCF7, DU145, OV1063 and OVCAR-3), the half maximal inhibitory concentration (IC50) having been found to be 5-20 times lower than that of the free drug. Studies with mice showed that the rHDL/PTX nanoparticles were substantially better tolerated than the corresponding dosages of either Taxol or Abraxane.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18176115     DOI: 10.1097/CAD.0b013e3282f1da86

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  34 in total

1.  Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis.

Authors:  Nicholas O Fischer; Ernesto Infante; Tomohiro Ishikawa; Craig D Blanchette; Nigel Bourne; Paul D Hoeprich; Peter W Mason
Journal:  Bioconjug Chem       Date:  2010-06-16       Impact factor: 4.774

Review 2.  High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.

Authors:  Rui Kuai; Dan Li; Y Eugene Chen; James J Moon; Anna Schwendeman
Journal:  ACS Nano       Date:  2016-02-25       Impact factor: 15.881

3.  Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF).

Authors:  Walter J McConathy; Sulabha Paranjape; Linda Mooberry; Sabitha Buttreddy; Maya Nair; Andras G Lacko
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

Review 4.  Learning from biology: synthetic lipoproteins for drug delivery.

Authors:  Huang Huang; William Cruz; Juan Chen; Gang Zheng
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-10-24

Review 5.  Cholesterol as a potential target for castration-resistant prostate cancer.

Authors:  Alexis L Twiddy; Carlos G Leon; Kishor M Wasan
Journal:  Pharm Res       Date:  2010-08-04       Impact factor: 4.200

Review 6.  HDL and microRNA therapeutics in cardiovascular disease.

Authors:  Danielle L Michell; Kasey C Vickers
Journal:  Pharmacol Ther       Date:  2016-09-03       Impact factor: 12.310

7.  Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting.

Authors:  Jie Tang; Rui Kuai; Wenmin Yuan; Lindsey Drake; James J Moon; Anna Schwendeman
Journal:  Nanomedicine       Date:  2017-04-18       Impact factor: 5.307

Review 8.  Modified natural nanoparticles as contrast agents for medical imaging.

Authors:  David P Cormode; Peter A Jarzyna; Willem J M Mulder; Zahi A Fayad
Journal:  Adv Drug Deliv Rev       Date:  2009-11-06       Impact factor: 15.470

9.  Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers.

Authors:  Ian R Corbin; Kenneth K Ng; Lili Ding; Andrea Jurisicova; Gang Zheng
Journal:  Nanomedicine (Lond)       Date:  2012-10-15       Impact factor: 5.307

10.  High-Density Lipoproteins for Therapeutic Delivery Systems.

Authors:  R Kannan Mutharasan; Linda Foit; C Shad Thaxton
Journal:  J Mater Chem B       Date:  2015-11-24       Impact factor: 6.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.